Pues si no han vendido y las tienen en 9,65 y mantienen la cita del ASCO ... ¿pero a donde creen que se les va a ir el precio?
SNTA
edito: pues yo voy promediado mejor que ellos en en 9,00 ... estos insiders son unos mierdas
MODO SNTA-ME-SACA-DE-QUICIO OFF
ha debido de salir en FORBES un articulo negativo hablando no por su nombre de producto , Vascepa, sino de "fish oil" que es como la nombran siempre en modo peyorativo.
37.000 shares en AH y -1,5%
AMRN
hay uno que lo achaca a lo de AVEO y los estudios en europa central y del este con la U.E.
los estudios de santa son en europa y usabicaciones
Estados Unidos, Arizona
Synta Farmacéuticos sitio Investigative Reclutamiento
Tucson, Arizona, Estados Unidos, 85715
Estados Unidos, California
Synta Farmacéuticos sitio Investigative Reclutamiento
Santa Monica, California, Estados Unidos, 90404
Estados Unidos, Georgia
Synta Farmacéuticos sitio Investigative Reclutamiento
Atlanta, Georgia, Estados Unidos, 30322
Estados Unidos, Illinois
Synta Farmacéuticos sitio Investigative Reclutamiento
Chicago, Illinois, Estados Unidos, 60637
Estados Unidos, Massachusetts
Synta Pharmaceutials Investigative Site Reclutamiento
Boston, Massachusetts, Estados Unidos, 02215
Estados Unidos, Carolina del Norte
Synta Farmacéuticos sitio Investigative Reclutamiento
Winston-Salem, Carolina del Norte, Estados Unidos, 27103
Estados Unidos, Ohio
Synta Farmacéuticos sitio Investigative Reclutamiento
Kettering, Ohio, Estados Unidos, 45429
Estados Unidos, Oregon
Synta Farmacéuticos sitio Investigative Reclutamiento
Portland, Oregon, Estados Unidos, 97227
Bélgica
Synta Farmacéuticos sitio Investigative Reclutamiento
Bruselas, Bélgica, 1200
Synta Farmacéuticos sitio Investigative Reclutamiento
Jette, Bélgica, 1090
Synta Farmacéuticos sitio Investigative Reclutamiento
Yvoir, Bélgica, 5530
Bosnia y Herzegovina
Synta Farmacéuticos sitio Investigative Reclutamiento
Banja Luka, Bosnia y Herzegovina, 78000
Synta Farmacéuticos sitio Investigative Reclutamiento
Mostar, Bosnia y Herzegovina, 88000
Synta Farmacéuticos sitio Investigative Reclutamiento
Sarajevo, Bosnia y Herzegovina, 71000
Synta Farmacéuticos sitio Investigative Reclutamiento
Tuzla, Bosnia y Herzegovina, 75000
Canadá
Synta Farmacéuticos sitio Investigative Reclutamiento
Hamilton, Canadá, L8V 5C2
Synta Farmacéuticos sitio Investigative Reclutamiento
Montreal, Canadá, H3A 1A1
Synta Farmacéuticos sitio Investigative Reclutamiento
Montreal, Canada, H3G 1A4
Synta Farmacéuticos sitio Investigative Reclutamiento
Ottawa, Canadá, K1H 8L6
Croacia
Synta Farmacéuticos sitio Investigative Reclutamiento
Pula, Croacia, 52100
Synta Farmacéuticos sitio Investigative Reclutamiento
Split, Croacia, 21000
Synta Farmacéuticos sitio Investigative Reclutamiento
Zagreb, Croacia, 10000
República Checa
Synta Farmacéuticos sitio Investigative Reclutamiento
Praga, República Checa, 180 00
Alemania
Synta Farmacéuticos sitio Investigative Reclutamiento
Halle, Alemania, 06120
Synta Farmacéuticos sitio Investigative Reclutamiento
Hamburgo, Alemania, 22045
Synta Farmacéuticos sitio Investigative Reclutamiento
Mainz, Alemania, 55131
Synta Farmacéuticos sitio Investigative Reclutamiento
Mannheim, Alemania, 68167
Synta Farmacéuticos sitio Investigative Reclutamiento
Offenbach, Alemania, 63069
Polonia
Synta Farmacéuticos sitio Investigative Reclutamiento
Cracovia, Polonia, 31-115
Synta Farmacéuticos sitio Investigative Reclutamiento
Olsztyn, Polonia, 10-357
Synta Farmacéuticos sitio Investigative Reclutamiento
Prabuty, Polonia, 82-550
Synta Farmacéuticos sitio Investigative Reclutamiento
Szczecin, Polonia, 70-891
Rumania
Synta Farmacéuticos sitio Investigative Reclutamiento
Cluj - Napoca, Rumanía, 400058
Synta Farmacéuticos sitio Investigative Reclutamiento
Cluj - Napoca, Rumanía, 400015
Synta Farmacéuticos sitio Investigative Reclutamiento
Craiova, Rumanía, 200385
Synta Farmacéuticos sitio Investigative Reclutamiento
Suceava, Romania, 720237
Federación de Rusia
Synta Farmacéuticos sitio Investigative Reclutamiento
Kazán, Rusia, 420029
Synta Farmacéuticos sitio Investigative Reclutamiento
Moscú, Federación de Rusia, 105229
Synta Farmacéuticos sitio Investigative Reclutamiento
Moscú, Federación de Rusia, 115478
Synta Farmacéuticos sitio Investigative Reclutamiento
San Petersburgo, Rusia, 197758
Synta Farmacéuticos sitio Investigative Reclutamiento
San Petersburgo, Rusia, 194075
Synta Farmacéuticos sitio Investigative Reclutamiento
Sochi, Rusia, 354057
Synta Farmacéuticos sitio Investigative Reclutamiento
Voronezh, Rusia, 394000
Serbia
Synta Farmacéuticos sitio Investigative Reclutamiento
Belgrado, Serbia, 11000
Synta Farmacéuticos sitio Investigative Reclutamiento
Sremska Kamenica, Serbia, 21204
España
Synta Farmacéuticos sitio Investigative Reclutamiento
Badalona, España, 08916
Synta Farmacéuticos sitio Investigative Reclutamiento
Barcelona, España, 08035
Reino Unido
Synta Investigación Farmacéutica del sitio Reclutamiento
Leicester, Reino Unido, LE2 7HL
Synta Farmacéuticos sitio Investigative Reclutamiento
Londres, Reino Unido, SE1 9RT
Synta Investigación Farmacéutica del sitio Reclutamiento
Londres, Reino Unido, SW3 6JJ
Synta Investigación Farmacéutica del sitio Reclutamiento
Sutton, Reino Unido, SM2 5PT
SNTA
PSTI
Informe. Estoy agotada y ya no proceso, pero parece horrible. Que alguien le eche un vistazo estos párrafos que pego y, si es posible, a las tablas del balance. En cualquier caso, me imagino que estará todo descontado.
The Company has sustained operating losses and expects such losses to continue in the foreseeable future. The Company's accumulated losses aggregated to $79,912 through March 31, 2013 and the Company incurred a net loss of $14,165 for the nine months ended March 31, 2013
The Company plans to continue to finance its operations with sales of equity securities, entering into licensing technology agreements such as the United Therapeutics Corporation (“United Therapeutics”) agreement, and from grants to support its R&D activity. In the longer term, the Company plans to finance its operations from revenues from sales of products.
Revenues for the nine months ended March 31, 2013 were $584,000 as compared to revenues of $615,000 for the nine months ended March 31, 2012. All such revenues are derived from our agreement with United, or the United Agreement. The Company estimated the performance period of the development of approximately 6.5 years. The license fee will be recognized on a straight line basis as revenue over the estimated development period.
Revenues for the three months ended March 31, 2013 were $194,000 as compared to revenues $230,000 for three months ended March 31, 2012. All such revenues are derived from the United Agreement. As discussed above, the Company estimated the performance period of the development of approximately 6.5 years and the license fee will be recognized on a straight line basis as revenue over the estimated development period.
The Company plans to continue to finance its operations with sales of equity securities, entering into licensing technology agreements such as the United Therapeutics Corporation (“United Therapeutics”) agreement, and from grants to support its R&D activity. In the longer term, the Company plans to finance its operations from revenues from sales of products.
Research and development expenses, net of participation of the Office of Chief Scientist, or OCS, and other grants, increased by 66% from $6,821,000 for the nine months ended March 31, 2012 to $11,313,000 for the nine months ended March 31, 2013. This increase is attributed to the material increase in our in-house research and development activity
General and administrative expenses for the nine months ended March 31, 2013 decreased by 12% from $4,836,000 for the nine months ended March 31, 2012 to $4,260,000 mainly due to a decrease in stock-based compensation expenses related to our employees and consultants.
General and administrative expenses for the three months ended March 31, 2013 decreased by 40% from $1,924,000 for the three months ended March 31, 2012 to $1,159,000 mainly due to a decrease in stock-based compensation expenses related to our employees and consultants, offset by an increase in salaries due to, among other things, hiring 4 new employees during the three months ended March 2012.
Financial income increased from $401,000 for the nine months ended March 31, 2012 to $842,000 for the nine months ended March 31, 2013 due to exchange rate adjustments and hedging transactions, as described below.
Financial income decreased from $436,000 for the three months ended March 31, 2012 to $253,000 for the three months ended March 31, 2013 due to hedging transactions, as described below.
Net loss for the nine and three months ended March 31, 2013 was $14,165,000 and $5,680,000, respectively, as compared to net loss of $10,659,000 and $4,174,000 for the nine and three months ended March 31, 2012, respectively. Net loss per share for the nine and three months ended March 31, 2013 was $0.26 and $0.10, respectively, as compared to $0.24 and $0.09 for the nine and three months ended March 31, 2012.
Cash and cash equivalents as of March 31, 2013 amounted to $27,821,000. This is an increase of $18,432,000 from the $9,389,000 reported as of June 30, 2012, which is mainly due to the public offering we closed in September 2012
We have accumulated a deficit of $79,912,000 since our inception in May 2001. We do not expect to generate any revenues from sales of products in the next twelve months. Our products will likely not be ready for sale for at least three years, if at all. Our cash needs will increase in the foreseeable future. We expect that in the coming years our research and development and general and administrative expenses will continue to grow.
http://ih.advfn.com/p.php?pid=nmona&article=57484110&xref=newsalerttweet
«Después de nada, o después de todo/ supe que todo no era más que nada.»
me voy a dormir.
http://www.forbes.com/sites/larryhusten/2013/05/08/another-disappointing-study-for-fish-oil-
esto lo colocaron también en la red.
supplements/https://twitter.com/chasingthealpha/status/332244957949751296/photo/1
joder, el ultimo parrafo es terrible. Pero no la sigo, no sabria decirte si es lo que esperaba el mercado o hay alguna sorpresa.
Porque si es lo que se esperaba, aqui no pasa nada.
PSTI
bona nit.
Yo creo que sí, que no hay nada nuevo y está todo descontado. Además, no es mediática.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
